Scholarlink

Background <p>Respiratory syncytial virus (RSV) is a highly contagious pathogen and a leading cause of bronchiolitis and pneumonia in young children, posing a significant global health burden. Currently, there are no effective treatment options available. Maternal immunization has emerged as a promising strategy to protect newborns from RSV. The RSVPref vaccine has shown efficacy in reducing RSV hospitalizations and severe cases in newborns aged 3 to 6&#xa0;months. Economic evaluations of maternal RSV vaccination are increasingly used to inform healthcare decision-making and resource allocation. These evaluations rely heavily on accurate disease burden estimates based on robust epidemiological data, as these assumptions strongly influence cost-effectiveness results and vaccine introduction decisions. This systematic review provides an overview of economic evaluations of RSV maternal immunization, with a focus on methods for estimating the epidemiological disease burden.</p> Methods <p>We will systematically search for studies in MEDLINE (via PubMed), EMBASE, the NHS Economic Evaluation Database (NHS EED), the HTA database, the Tufts CEA Registry, LILACS, and Web of Science. The search strategy will encompass three main categories, (1) economic evaluation, (2) vaccines, and (3) respiratory syncytial viruses, including studies published since 2000 in any language. Two independent reviewers will extract data via a validated form. The quality of reporting of the included studies will be assessed via the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 checklist. A descriptive and interpretative synthesis of the obtained extracted data will be performed.</p> Discussion <p>RSV immunization is the most crucial option for reducing the disease burden imposed by the virus in children. This study will systematically review the methodologies used to develop accurate and reliable epidemiological estimates, which are essential components of economic evaluation studies that will support the global implementation of the RSV maternal vaccine.</p> Systematic review registration <p>PROSPERO CRD42024549989.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Disease burden estimates in economic evaluation studies of Respiratory Syncytial Virus (RSV) maternal immunization: a systematic review protocol

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月26日

查看全文
  • Sophia Aguiar Monteiro Borges,
  • Felipe Lima Barreto,
  • Alexandre de Oliveira Esteves,
  • Ana Carolina Nonato,
  • Erick Ohanesian Polli,
  • Natacha Regina de Moraes Cerchiari,
  • Ana Marli Christovam Sartori,
  • Patrícia Coelho de Soárez

摘要

Background

Respiratory syncytial virus (RSV) is a highly contagious pathogen and a leading cause of bronchiolitis and pneumonia in young children, posing a significant global health burden. Currently, there are no effective treatment options available. Maternal immunization has emerged as a promising strategy to protect newborns from RSV. The RSVPref vaccine has shown efficacy in reducing RSV hospitalizations and severe cases in newborns aged 3 to 6 months. Economic evaluations of maternal RSV vaccination are increasingly used to inform healthcare decision-making and resource allocation. These evaluations rely heavily on accurate disease burden estimates based on robust epidemiological data, as these assumptions strongly influence cost-effectiveness results and vaccine introduction decisions. This systematic review provides an overview of economic evaluations of RSV maternal immunization, with a focus on methods for estimating the epidemiological disease burden.

Methods

We will systematically search for studies in MEDLINE (via PubMed), EMBASE, the NHS Economic Evaluation Database (NHS EED), the HTA database, the Tufts CEA Registry, LILACS, and Web of Science. The search strategy will encompass three main categories, (1) economic evaluation, (2) vaccines, and (3) respiratory syncytial viruses, including studies published since 2000 in any language. Two independent reviewers will extract data via a validated form. The quality of reporting of the included studies will be assessed via the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 checklist. A descriptive and interpretative synthesis of the obtained extracted data will be performed.

Discussion

RSV immunization is the most crucial option for reducing the disease burden imposed by the virus in children. This study will systematically review the methodologies used to develop accurate and reliable epidemiological estimates, which are essential components of economic evaluation studies that will support the global implementation of the RSV maternal vaccine.

Systematic review registration

PROSPERO CRD42024549989.